Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 1/20 | 0.40 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.36 |
| ▸ | BACE1 | P56817 | 2/20 | 0.35 |
| ▸ | MAOA | P21397 | 2/20 | 0.34 |
| ▸ | MAOB | P27338 | 2/20 | 0.34 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14168674 | 0.83 | CHRNA7 (0.44) | L3MBTL1 | |
| 5-Methyl-3-Phenethyl-5-Phenyl-4,5-Dihydroisoxazole (Enantiomeric Mix) SCHEMBL2921112 | 0.82 | ITGB1 (0.38) | ITGB1ITGA4KCNH2BACE1 | |
| SCHEMBL14028657 | 0.74 | ACHE (0.40) | ITGB1ITGA4KCNH2 | |
| 3-[2-(4-Hydroxy-Phenyl)-Ethyl]-5-Methyl-5-Phenyl-4,5-Dihydro-Isoxazole (Enantiomeric Mix) SCHEMBL2920444 | 0.73 | ESR1 (0.38) | ITGB1ITGA4 | |
| SCHEMBL2912160 | 0.73 | SIGMAR1 (0.38) | BACE1 | |
| SCHEMBL22018298 | 0.72 | CRBN (0.32) | — | |
| SCHEMBL21964021 | 0.67 | — | — | |
| SCHEMBL24517811 | 0.67 | TP53 (0.36) | BACE1MAOAMAOBGAAALDH1A1 | |
| Ethane SCHEMBL21049496 | 0.65 | ALDH1A1 (0.61) | KCNH2MAOAMAOBALDH1A1 | |
| SCHEMBL62125 | 0.64 | ALDH1A1 (0.69) | KCNH2MAOAMAOBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680290-B2 | Isoxazoline derivatives and their use as herbicides | SYNGENTA LIMITED (GB) | 2014-03-25 | — | — | US | disclosed |
| US-20080139390-A1 | Isoxazoline Derivatives and Their Use as Herbicides | SYNGENTA LIMITED (GB) | 2008-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139390-A1 | Isoxazoline Derivatives and Their Use as Herbicides | MTX1, MTX2, CHRM1 | ITGB1 2130/4885ITGA4 3066/4885KCNH2 237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.